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Abstract The primary goal of breast and ovarian cancer
screening is to minimize the cases of advanced disease and
therefore its mortality rate. For hereditary breast and ovarian
cancer, one method to reach this goal is to disseminate
genetic risk information among family members. However,
experience tells us that this information does not always
reach family members in a timely manner, if at all. There
are many moving parts to a decision to disclose genetic risk
information within a family, and the lack of detail and
cohesion in current guidelines do a disservice to hereditary
breast cancer prevention. Utilizing legal, medical, and pol-
icy databases for literature, case law and policy documents
relating to communication of genetic test results within
families, as well as a consultative process with representa-
tive stakeholders, a points to consider has been developed to
address a number of issues that might impact the ability and
willingness of patients to inform family members of genetic
risk. These include: what is “genetic information”; who is
the “family”; why should patients inform their family mem-
bers; and how should health professionals be involved in
this process? This represents only an initial step towards
fostering better communication within families. Additional
research is needed to determine the best methods for en-
couraging this communication and motivations for disclos-
ing or not and to promote the development of a solution,
considering the complexity of human relationships and the
probabilistic nature of genetic information.
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Introduction
Stemming from the increased availability in genetic se-
quencing technologies, a new emphasis has emerged on
the intrafamilial communication of a patient's genetic infor-
mation back to their family members (Wiseman et al. 2010).
With the growth of genetic medicine and genetic testing, “it
is reasonable to assume that growing numbers of relatives
would wish to be informed of their risks” (Lucassen and
Parker 2010). For diseases like hereditary breast and ovarian
cancer, communicating a patient's cancer diagnosis or ge-
netic risk profile back to their family provides family mem-
bers the opportunity to take advantage of additional testing,
screening, and other cancer risk-reducing interventions that
become available to those with a family history that suggests
higher risk (Carroll et al. 2008).
Despite the importance of intrafamilial communication,
hurdles have emerged to its widespread promotion by health
care professionals and completion by patients. Messages
surrounding intrafamilial communication emphasize the
choice patients have in choosing whether to disclose results
to their relatives, potentially decreasing the urgency of the
disclosure (Forrest et al. 2007). In addition, research has
shown that intrafamilial communication is a complex and
delicate task. It requires patients to first absorb complicated
information from health care professionals about their own
health (Meiser et al. 2012; MacDonald et al. 2010) and then
communicate this delicate information to family members
with diverse educational and generational backgrounds
while navigating family dynamics (Peters et al. 2011; Foster
et al. 2004; Claes et al. 2003; Hallowell et al. 2005). Further,
for some patients, the act of considering whether to disclose
information to their family members will compete with the
sometimes more time-sensitive need to consider their own
health care, as such information often becomes available
following a diagnosis of cancer or high-risk status (Meiser
et al. 2012).
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For those patients willing to disclose, the role that health
care professionals play in encouraging and supporting
patients' efforts to communicate with family members is
unclear. Guidelines and policy for health care professionals
with respect to counseling patients for intrafamilial commu-
nication are scant (Forrest et al. 2007; Nycum et al. 2009a).
In response, diverse groups of health care professionals have
called for research and guidance in this area (Kissane et al.
2012; MacDonald et al. 2010; Pelletier and Dorval 2004).
The importance of a more cohesive and detailed strategy for
intrafamilial communication is demonstrated by the propos-
al of legislation to allow health care professionals to inform
their patients' relatives of their risk for genetic disease with-
out consent (Patty 2012) and litigation over a medical doc-
tor's professional responsibility to inform relatives of their
patient of the risks of inherited disease (Watters v. White
2012). These fill the vacuum with legal solutions that might
not be appropriate or effective.
In our previous research, we identified major themes
underlying the development of policy with respect to intra-
familial communication, namely: (1) Who is a family mem-
ber?; (2) What types of information should be disclosed?;
(3) What is the expectation for patients with respect to
intrafamilial communication?; and (4) What is the role for
health professionals in any system of intrafamilial disclo-
sure? (Nycum et al. 2009a). For this paper, we narrow the
focus to hereditary breast and ovarian cancer primarily due
to its prevalence, especially in the literature, in much of the
discussion surrounding the disclosure of risk information to
family (intrafamilial or otherwise). In an effort to guide
policy development for health care professionals and en-
courage intrafamilial communication by patients, we have
conducted a review of applicable norms and literature, fol-
lowed by a consultation with key stakeholders. From this,
we suggest the key points to consider underlying the above
five themes for policy- and decision-makers to consider
when formulating guidance in this area.
Methods
Document collection
The currently applicable normative frameworks surrounding
intrafamilial communication of hereditary breast and ovar-
ian cancer in Canada, France, Australia, USA, and UK were
determined by reviewing the following classes of docu-
ments: (1) laws and regulations (provincial and federal)
currently in force; (2) applicable case law; (3) guidelines
and rules adopted by professional associations; (4) direc-
tives and guidelines adopted by hospitals and health care
providers; and (5) policies adopted by patient advocacy
groups.
Relevant laws and regulations in force were identified by
searches in official compendia of laws and regulation. Rel-
evant case law was obtained by searching legal electronic
databases such as SOQUIJ, QuickLaw, and WestlawCars-
well. Relevant legislation examined concerned human rights
and freedoms (particularly, privacy and protection of per-
sonal information), civil liability in general, duties of health
professionals, children's rights, parental rights and duties
(family law), state duties towards parents and children in
the provision of health care, and the related case law therein.
Guidelines, policies, and recommendations published
since 1995 were obtained by conducting a review of Hum-
Gen.org (www.humgen.org/int/_ressources/Method_en.pdf,
a database of laws and policies related to human genetics),
keyword-driven searches of other databases including
PubMed and Google, and searches of relevant organization-
al websites.
Academic literature on intrafamilial communication of
hereditary breast and ovarian cancer literature was obtained
using internet search engines, specialized databases (e.g.,
PubMed, Philosophers' Index, Kennedy Institute of Bioeth-
ics, and Google Scholar), libraries, and manual searches of
relevant publication indexes and publications. All databases
and search engines were searched using the following
search terms: “famil*” [and] “genetic” or “cancer” [and]
“communicat*.”
Document analysis
Two members of the research team (LB and KAM) identi-
fied the key points to consider through content analysis of
the normative documents and academic literature. Guided
by the themes previously identified as underlying intrafami-
lial obligations to communicate, normative documents were
first examined to identify key considerations underlying
each theme (Nycum et al. 2009a). To supplement the anal-
ysis, alternative regulatory scenarios were obtained by ex-
amining the regulatory frameworks in Australia, UK,
France, and the USA, while additional considerations were
identified through searches of the academic literature. From
this analysis, a preliminary draft of the points to consider
was assembled.
Consultative process
Validation of the points to consider was conducted by an
iterative two-step consultative process, which took place in
spring and autumn of 2010. In the first step, the preliminary
draft points to consider was circulated among representative
stakeholders purposefully drawn from the following stake-
holder groups: nursing, genetic counseling, and patient ad-
vocacy communities for hereditary breast and ovarian
cancer. Participants were gathered from the Montreal region
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and identified through existing networks. In the round table
discussion that took place in Montreal in April 2010, par-
ticipants were asked to comment on the content of the draft
points to consider, identify key priorities, and supplement
the points based on experience. The draft points to consider
was revised to reflect input gained from the first consulta-
tion. In the second step, the revised points to consider was
circulated and presented as oral presentations to audiences
of researchers and trainees in two separate forums: the
Canadian Association of Genetic Counsellors Annual Edu-
cation Conference, held in Halifax, NS, in October 2010,
and the National Conference on Genomics and Public
Health, held in Bethesda, Maryland, in December 2010.
The points to consider was further modified to reflect feed-
back obtained from conference participants following each
presentation. Revisions were made under the auspices of the
Chatham House Rule, as no comments were attributed to
any individual or organization.
Results
Who is part of the genetic family?
Any obligation to disclose genetic information to family
members rests upon the determination of who, exactly, is
“family.” This may seem like a simple question, but the
genetic context raises a number of complexities. Should
the family be defined exclusively by genetic or blood ties?
What degree of blood relation should be required when
considering inclusion in the family? Should factors other
than biology be taken into consideration when defining the
genetic family? For example, should individuals with strong
social or legal ties who could have an interest in the infor-
mation, such as non-biological children, spouses, partners,
and in-laws, be included as members of the family when it
comes to genetic information?
Definitions of genetic family have been debated among
scholars, and both traditional and broad views have been
advocated. According to the traditional view—a biologic
model—the genetic family is defined primarily by blood
ties and traditional legal relationships, such as marriage
and reproduction (Laurie 2002): those who have an interest
in the information, based on individual health concerns or
personal reproductive choices. Thus, the genetic family
would be limited to blood relatives and spouses and would
exclude adopted children as well as same sex and cohabitat-
ing partners or others who may have a need to know the
information aside from their own personal health. While on
the surface this definition appears unequivocal in identifying
who is a genetic family member, it is problematic as there is
potentially no limit to the degree of biologic relation that
could be included, however far removed. This disregards the
practical realities of family dynamics, by asking patients to
disclose genetic information to distant blood relatives with
whom the patient has little to no preexisting social relation-
ship. It also ignores the interests of non-blood relations.
Further, it ignores the contribution that other family mem-
bers could make in disseminating family history information
(Koehly et al. 2009).
In contrast, there is a broad view of the genetic family
that accounts for both biological and social interests.
According to this biosocial model, in the absence of a
biological relationship, a preexisting social relationship
could substitute as the defining criteria for identifying a
family member (Gilbar 2005). As a consequence, a wide
range of relationships would qualify as familial relation-
ships, such as same sex partners. In addition, in the complete
absence of a preexisting social relationship, this model
could excuse individuals from classification as family mem-
bers, even if there is a biological relationship. This, for
example, would allow for exclusion of a sperm donor from
family or distant cousins who have never met. The emphasis
on the sociological aspect, however, is not without criticism.
One can question the reasoning or fairness of refusing to
communicate with close family members in families that are
in the midst of breakdown or with whom a patient has never
had a personal relationship (assuming the patient knows of
the family members and has the means and knowledge to
contact them). This disadvantage aside, the flexibility
afforded by the biosocial model represents a key advantage,
as the model is capable of adapting to the myriad of legal
and social relationships found within today's modern family.
Recognizing the unique challenges brought about
through knowledge of genetic information, many organiza-
tions, including ethics and medical genetics groups and
physician and patient advocacy groups, have attempted to
acknowledge both the familial and individual nature of
genetic information (Forrest et al. 2007). Some European
bodies have addressed the definition of the family directly
and have adopted either narrow or broad views of the
family. For example, an expert subgroup within the Euro-
pean Commission has adopted an approach closely resem-
bling the biologic view by acknowledging that genetic
testing is of consequence to blood relatives such as offspring
(European Commission: The Independent Expert Group
2004). In contrast, both the French National Consultative
Ethics Committee and German Society of Human Genetics
have broadened this biologic definition, noting that results
of a genetic test are of interest to the extended family,
including legal relatives such as spouses (France National
Consultative Ethics Committee for Health and Life Sciences
(CCNE) 2003; German Society of Human Genetics 1998).
In Canada and the USA, however, the various guidelines
examined applied primarily to physician disclosure to fam-
ily, rather than intrafamilial disclosure. These guidelines do
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not adopt positions defining the genetic family, instead
affirming that with regards to genetic information, the pri-
vacy considerations of the individual should prevail (Wat-
son and Greene 2001; Canadian Medical Association 1999;
American Society of Human Genetics 2000).
While these debates regarding the appropriate definition
of the family still persist, some jurisdictions have adopted
legislation (generally more authoritative than guidelines)
that defines family in relation to genetic information. The
USA enacted the Genetic Information Non Discrimination
Act (GINA) in 2008, which seeks to prevent the use of
genetic information of individuals or their family members
as grounds to deny access to health insurance or employ-
ment. In defining family, the act identifies relatives up to
and including fourth degree relatives (U.S. Bill H.R. 493
Genetic Information Nondiscrimination Act of 2008 (110th
Cong.) 2008). Further, the definition also includes eligible
dependents, though eligible dependents are limited to mar-
ried spouses and adopted children (U.S. Bill H.R. 493
Genetic Information Nondiscrimination Act of 2008 (110th
Cong.) 2008). By emphasizing blood relatives and tradition-
al legal relationships, the position of USA closely resembles
the expanded biologic view of genetic family. The state of
Illinois has adopted similar legislation, but also includes any
individual related by blood or law to the patient or his or her
child or spouse, thus greatly increasing the pool of potential
family members (Genetic Information Privacy Act 2009).
Australia adopted guidelines for the use and disclosure of
genetic information to patients' genetic relatives, who are
defined to include only individuals related by blood (Gov-
ernment of Australia 2009). Furthermore, disclosure is rec-
ommended to up to third degree relatives. These guidelines
apply to disclosure by private sector health professionals
(explicitly excluding public sector professionals/facilities
and the government) without the consent of the patient,
which might be why the boundaries of genetic relatives
are so narrowly defined. In contrast, Australia previously
considered legislation (never adopted) that included a broad
definition of genetic family. In the Genetic Privacy and Non
Discrimination Bill (Government of Australia 1998), which
had similar objectives to the US GINA, a family member
was defined as being either biological or legal relatives who
would have a material interest in the genetic information.
However, the relative weight assigned to each factor (bio-
logical versus legal relative) in establishing status as a
family member was unclear, as was the component of “ma-
terial interest.”
There are a wide variety of definitions of family, ranging
from the very narrow and specific to the very broad. How-
ever, these definitions are not applied specifically in the
context of intrafamilial communication, but rather for the
protection of genetic information or communication by
health professionals. It would be reasonable, then, to
propose that for intrafamilial communication, the family
could be considered from a more expansive perspective.
Points to consider: definition of the family
1. The genetic family has been defined to include blood ties,
preexisting social relationships, or both.
2. A social relationship can be an important factor in deciding to whom
to disclose genetic information. Spouses, adopted children, step-
parents, and partners could all have an interest in knowing this
information even if it will not affect their personal health, such as for
reproductive planning or making health decisions in the event of the
patient's or other family member's incapacity.
3. An ideal definition of family would strike an appropriate balance
between the biological and the social (marriage, cohabitation,
adoption, etc.) when characterizing an obligation to communicate, as
well as the purpose of and need for the information, in order to
incorporate the varied familial relationships across society.
4. The degree of the relationship should also be a consideration. There
is no good rule as to how broad family should be defined (some laws
use fourth degree relatives and others third degree), but the more
tenuous degree of blood relation the less beneficial the disclosure will
be compared to the loss of privacy and confidentiality for the patient.
5. A definition of family should also consider the health interests of the
family member, regardless of the closeness of the relationship
between the patient and family member or their blood ties. For
example, siblings still have a strong interest in the information even if
their personal relationship with the patient is poor: the absence of a
social relationship in this instance should not be a determining factor
for disclosure.
What constitutes genetic information that patients should
be encouraged to disclose?
Advances in the genetic sequencing and understanding of
cancer have created new categories of information. Heredi-
tary breast and ovarian cancers illustrate the questions raised
when determining the kind of information patients should be
encouraged to disclose. Is it only information discovered
through DNA-based genetic testing from laboratory analy-
ses? Or are histological analyses of tumors that would
strongly suggest hereditary cancer included? Is information
from breast cancer risk prediction models suggestive of a
probability of heritable cancer risk included? Is family his-
tory of breast cancer genetic information?
What is “genetic information?”
The debate over what constitutes genetic information raised
in other contexts, such as insurance (O'Neill 1997), echoes
the question raised here: what is genetic information for
which family members have an interest? Inquiries have
traditionally focused on laboratory DNA testing that pro-
vides information about heritable gene variants (American
Society of Clinical Oncology 2003). However, as technolo-
gy evolved, other non-DNA-based testing strategies have
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emerged that have the capacity to produce information sug-
gestive of heritable genetic variants for which family mem-
bers may have an interest. For example, with respect to
breast cancer, so-called triple negative breast tumor pathol-
ogies are the results of non-DNA-based pathology testing
that suggests presence of BRCA1 or BRCA2 mutations
(Peshkin et al. 2010; Meyer et al. 2012). Thus, questions
are raised as to whether patients should be counseled of the
consequences such results may have for their families.
In addition to lab-based genetic testing, other methods
have arisen to estimate a patient's risk of carrying a genetic
mutation and developing cancer, which might be of impor-
tance to family members. A number of genetic risk assess-
ment models, such as BOADICIA, BRCAPRO, the Myriad
tables, IBIS, and others (Antoniou et al. 2008; Jacobi et al.
2009), have been developed to incorporate information such
as family history of cancer, lifestyle, and the presence of a
particular genetic mutation in the family. They are intended
to provide a more accurate evaluation of risk than family
history alone. Patients are placed in low-, medium-, or high-
risk categories that can be used to refer for further testing, as
many guidelines recommend genetic testing only if the
probability of a mutation is above a certain percentage
(Antoniou et al. 2008). The probabilities generated by these
models can be considered genetic information since they
indicate a potential level of risk for developing cancer or
having a genetic mutation and act as gatekeeper for access to
subsequent testing and cancer risk-reducing medical inter-
ventions (Carroll et al. 2008).
Family history is a further source of genetic information.
As genetic knowledge expands, “benign” family histories,
long integral to medical care, are acquiring greater signifi-
cance as scientifically valid sources of medical or genetic
information (Guttmacher et al. 2004; Claes et al. 2003). In
relation to breast cancer, family history information is re-
quired for targeting interventions at high-risk individuals
who can most benefit from available preventive strategies
(Carroll et al. 2008). Consequently, the diagnosis of breast
cancer or the discovery of a genetic mutation in a patient
becomes family history information that relatives have an
interest in knowing.
Genetic information in current guidance
There are multiple views in the documents we examined on
the breadth of what constitutes genetic information, though
there is general agreement that information obtained from
clinically accepted laboratory-based genetic tests constitutes
genetic information. Some guidelines, however, view this as
the only source of genetic information and limit genetic to
“inheritable.” For example, the United Nations Educational,
Scientific, and Cultural Organization (UNESCO) defines
human genetic data as “information about heritable
characteristics of individuals obtained by analysis of nucleic
acids or by other scientific analysis” (UNESCO 2003).
A number of organizations and governments, though,
have adopted a broad view of what constitutes genetic
information, covering a wider range of information, which
includes family history and could be extended to analysis of
risk prediction models. In the USA, GINA provides such a
definition and includes genetic tests, the genetic tests of
family members, and the manifestation of a disease or
disorder in family members (U.S. Bill H.R. 493 Genetic
Information Nondiscrimination Act of 2008 (110th Cong.)
2008). Other countries that apply a broad definition of
genetic information include the UK, where genotype, phe-
notype, and family information are explicitly included (Hu-
man Genetics Commission 2002; Royal College of
Physicians et al. 2011), and the Council of Europe where:
“the expression ‘genetic data’ refers to all data, of
whatever type, concerning the hereditary characteris-
tics of an individual or concerning the pattern of
inheritance of such characteristics within a related
group of individuals.” (Council of Europe and Com-
mittee of Ministers 1997)
Recent guidelines from Australia for the disclosure of
genetic information by health professionals also take a broad
view of this information, noting that it can come from a
wide range of sources, including family history, and can
confirm a particular condition or predict the likelihood of
carrying a mutated gene (Government of Australia 2009).
Consequences for broad and narrow conceptions of genetic
information
The use of a broad or narrow definition of genetic informa-
tion for the purposes of encouraging intrafamilial commu-
nication can have important consequences for family
members and patients alike. For family members, the con-
sequences of a narrow definition based solely on inheritable
characteristics ascertained through laboratory testing means
that other information—risk prediction scores or tumor pa-
thology results indicative of hereditary cancer—would not
be information that patients are encouraged to share with
their families. This is important because other information
such as family history of breast cancer is often what prompts
physicians to initially suggest genetic testing, cascade
screening, or to utilize a risk assessment model (Acheson
et al. 2000; Panchal et al. 2008). Thus if patients are not
encouraged to disclose this information to their families or
made aware of the benefits, family members might not gain
access to testing.
Adopting a broader definition of genetic information that
would include risk assessment scores, tumor pathology
results, and family history could, however, come at the
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expense of the patient's own interests. Despite the presence
of laws designed to prevent it, concerns about the possibility
of misuse of genetic information or family history in deci-
sions regarding employment or access to insurance remain
widespread (Schmitz and Wiesing 2006; Lucassen et al.
2006). If patients were aware of the expectation of inform-
ing their relatives of a wider range of medical test results and
information, they may hesitate to seek testing for a number
of reasons, including concern for the consequences of hav-
ing the information as part of their own medical file. Indeed,
the concern is not only about how this information will be
used, but also about how family members will react, how
they will view the patient, or how the patient views him or
herself in relation to others in the family (Nycum et al.
2009b; Gilbar 2007).
Points to consider: genetic information
1. Genetic information is information that provides insight into a
person's genetic makeup and risk for particular diseases and
disorders. It incorporates a wide variety of medical information,
including:
(a) Laboratory analyses including DNA and non-DNA-based testing
suggestive of heritable conditions
(b) Information from risk assessment models
(c) Family medical history
(d) Genetic testing of other family members
2. A patient's risk for developing cancer and the basis for that risk
should be included as part of the genetic information that is conveyed
to family members, as it is key to fully understanding familial risk.
Patients must be provided with information that explains what their
risk means and which dispels any misconceptions about an increase
or decrease in risk.
3. When considering what constitutes genetic information that patients
should be encouraged to share with their families, attention should be
paid to balancing the benefits a broader definition would bring to
families with the cost it would incur on patients.
Intrafamilial disclosure of genetic information as a personal
responsibility
In our previous work on this subject (Nycum et al. 2009a),
the focus was whether there is conceivably a legal obligation
for patients to communicate genetic information to family
members, especially as pertains to Canadian law. Here, our
focus turns to the potential for personal responsibility. The
distinction between legal and personal is one of flexibility,
jurisdiction, and oversight. The balancing of these factors
suggests that a legal obligation would be ill-advised, and in
any event, a legal obligation has yet to be established in any
jurisdiction. Thus, a personal responsibility for patients to
disclose genetic information to family is preferable and
more realistic.
A personal responsibility to disclose genetic information
A personal responsibility to disclose genetic information is
more permissive in describing what we expect to happen in
family relationships, as opposed to a legal obligation, which
is more about what we require. In this instance, it permits a
patient to decide what, to whom, when, and how to disclose
information that could have an impact on the health of a
family member, as well as on the family member's relation-
ship with the patient. The familial context of each patient is
different (Wiseman et al. 2010), and a personal responsibil-
ity recognizes this.
This responsibility has adherents in national and interna-
tional guidelines and policies that promote patient disclosure
of genetic risk to their families. Although these are often not
detailed, they are a starting point for discussion.
In Germany, a personal responsibility to communicate
genetic risk is explicit. “A moral obligation of family mem-
bers to share their knowledge of their genetic makeup can be
seen, as well as a moral obligation of partners to inform each
other of their medical genetic problems, insofar as the latter
concern children they may have in common” (German So-
ciety of Human Genetics 1998). France also takes a more
explicit view of the obligation of patients. The National
Consultative Ethics Committee for Health and Life Sciences
makes clear that the patient has the moral responsibility
(though not the legal) to disclose pertinent information to
those who could benefit (France National Consultative
Ethics Committee for Health and Life Sciences (CCNE)
2003).
In the UK, the General Medical Council recognizes that
most patients will share genetic information with relatives if
properly advised of the health implications of the informa-
tion (General Medical Council 2009). The Nuffield Council
on Bioethics is clear that patients “acting responsibly would
normally wish to communicate important genetic informa-
tion to other family members who may have an interest in
that information, and… that the primary responsibility for
communicating genetic information to a family member or
other third party lies with the [patient] and not with the
doctor who may, however, do this at the request of the
person concerned” (Nuffield Council on Bioethics 1993).
This statement places responsibility for disclosure solely
with the patient, though it does not provide further direction
as to how and when patients should do so. Finally, the Joint
Committee on Medical Genetics recently released guidance
on consent in genetic practice, emphasizing the importance
that genetic information might hold for family members and
recognizing the patient as a potential source of the disclo-
sure (Royal College of Physicians et al. 2011).
Other guidance implies a responsibility for patients to
inform family of risk. The American Society of Human
Genetics states that “[a]t a minimum, the health care
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professional should be obliged to inform the patient of the
implications of his/her genetic test results and potential risks
to family members” (American Society of Human Genetics
and Social Issues Subcommittee on Familial Disclosure
1998). This policy in effect places responsibility on patients
to inform family members of risk, but does explicitly advise
health care professionals to direct patients to do so.
All of this guidance recognizes the importance of family,
rather than others such as physicians, as being the ones to
share genetic information with other family members. There
is evidence that in the majority of cases, patients will even-
tually share their genetic status with relevant family mem-
bers (Nuffield Council on Bioethics 1993; Hallowell et al.
2003; Julian-Reynier et al. 2000; Bradbury et al. 2007;
Cheung et al. 2010). This might be based on the closeness
of the relationship or a duty felt towards others, rather than
any explicit personal responsibility (Hallowell et al. 2003).
Although disclosure might not be immediate, the fact that it
usually happens (eventually) should be comforting to those
who worry about whether family will be informed of this
important information.
Of course, in a voluntary system of personal responsibil-
ity, not all patients will choose to disclose—such is the nature
of this system. However, with strong support for voluntary
disclosure, patients can be reassured and educated in how to
share this information.
Disclosure to children
Special consideration must be given to whether a personal
responsibility to disclose genetic information to family
extends to young children. Informing children about genetic
risks is something that many parents struggle with. Issues
with guilt (Clarke et al. 2008) and stress in the relationship
can determine whether, when and how a parent tells his or
her children about a genetic risk. The decision involves the
balancing of many factors such as age and ability to com-
prehend. Other factors, such as severity of the disease and
availability of prophylactic measures, are specific to a par-
ticular disease. There are no clear rules on how and when to
inform children of genetic risk, although informing them
prior to an age when they understand what the information
means and/or can be proactive is discouraged (Mackenzie et
al. 2009), indicated as well by parents being advised to
delay involvement of children in the genetic counseling
process (Bradbury et al. 2007).
It is generally recommended, at least at the present time, that
children should not be tested for adult onset genetic diseases
until they are able to exercise their autonomy (American
Society of Human Genetics and American College of Medical
Genetics 1995; Public and Professional Policy Committee of
the European Society of Human Genetics 2009; Mackenzie et
al. 2009; American Academy of Pediatrics and Committee on
Bioethics 2001; Royal College of Physicians et al. 2011).
However, there is no such limitation on informing children
that they might be at genetic risk (Mackenzie et al. 2009).
Some studies have shown that parents will inform young
children (e.g., below age 13) regardless of their ability to truly
understand and before monitoring, genetic testing, or prophy-
lactic surgeries such as mastectomies or oophorectomies (sur-
gical removal of the ovaries) are recommended (Mackenzie et
al. 2009; McGivern et al. 2004).
There are risks, such as emotional harm, that accompany
in telling a child of genetic risk at an age when they are too
young to fully comprehend its meaning or participate in
monitoring, testing, and screening programs. However,
delaying disclosure could lead to a feeling of dishonesty
on the part of the parent (Bradbury et al. 2009; Cappelli et
al. 2005; American Academy of Pediatrics and Committee
on Bioethics 2001), and the child might still be able to
determine through other methods (non-verbal cues, over-
heard fragments of discussion, knowledge of ongoing med-
ical treatment) that something is wrong and they are not
being told. An additional consideration supporting disclo-
sure is that knowledge of risk at a young age can also help
reduce behaviors that increase risk (Clarke et al. 2008),
although the evidence of this is not conclusive (Bradbury
et al. 2009).
There is no established framework as to when and how
parents should inform children about their genetic risk for
hereditary breast and ovarian cancer and whether children
should be part of the counseling process. The parent's
need to inform the child and the child's ability to under-
stand are considerations. Although waiting until a child is
of an age when monitoring and screening are recommen-
ded has been advised (early adulthood), disclosing when
they are able to understand and adopt risk-reducing behav-
iors (such as adolescence) might provide some level of
benefit. In addition, parents might need the guidance of
health professionals—who are often better equipped to
understand the types of information that should be dis-
closed at a given age, as well as the best way of going
about it—when disclosing this information to children
(McBride et al. 2010).
The right not to know
Although there should be a personal responsibility for
patients to inform family members of genetic risk, there
might be circumstances when those family members legiti-
mately do not want to know: this is their purported right not
to know. Traditionally, the right not to know one's genetic
status has been considered in the context of the physician–
patient relationship. The existence of this right among fam-
ily members, however, has been and continues to be debated
(Gilbar 2007).
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Recognized by international ethical and legal instru-
ments, including the UNESCO Universal Declaration on
the Human Genome and Human Rights (UNESCO 1997)
and the European Convention on Human Rights and Bio-
medicine (Council of Europe 1997), the right not to know
dictates that “everyone is entitled to know any information
collected about his or her health. However, the wishes of
individuals not to be so informed shall be observed” (Coun-
cil of Europe 1997). In opposition to a presumption of this
right, some have proposed that the right is activated through
explicit choice (Andorno 2004), meaning that a family
member must state their desire not to know before the
patient is obligated to not inform them. Potentially, trying
to discern preferences without guidance from the family
member can create a dilemma for the patient: by not dis-
closing the patient might be observing this right, but they
would also fail to fulfill the “need for the provision of
information sufficient to allow people to make meaningful
choices” (Laurie 1999). In addition, by trying to determine a
relative's wishes, the patient might have to disclose the
existence of a potential risk (e.g., by asking “do you want
to know your genetic risk?”) so that the purpose of the right
not to know is defeated (Laurie 1999).
For these reasons, the personal responsibility to commu-
nicate genetic risk information should be tempered by a
more informal observance of the right not to know. This
would permit a well-grounded decision not to inform with-
out an explicit refusal by a family member, if the patient
reasonably believes that the family member would not want
to receive the information: “patients can reach a decision
after a careful process based on the sharing of thoughts,
beliefs, and desires in the family” (Gilbar 2005). This is not
a perfect solution, as patients will not always know the
wishes of others in their family and poor intrafamilial rela-
tionships could create additional difficulties. However, con-
sidering the complexity raised above concerning the
deciphering of a family member's wishes without explicit
statements, granting patients' discretion to disclose or not or
to gain more information from family members regarding
their wishes is perhaps the most realistic solution.
Points to consider: personal responsibility to communicate genetic risk
to family members
1. Disclosure of genetic risk by patients to their families should be a
personal and voluntary obligation, as the practical implication of a
personal responsibility is to create an atmosphere that encourages and
promotes voluntary disclosure.
2. The decision to disclose should be made by the patient, following
guidance from a health professional when needed.
3. Patients should be informed of the familial nature of genetic
information and their obligation to communicate this information to
family members as part of pre- and posttest genetic counseling.
4. Children, when sufficiently mature, should not be automatically
excluded from parents' efforts to inform family members of genetic
risk, as they have at least as much interest in the information as other
members of the family. Genetic risk information can be both valid
and useful for children to know and can permit them to incorporate
behaviors that lessen risks. However, this knowledge can also have a
negative impact, such as emotional distress from the realization that
the risk is lifelong, thus disclosure to children should be done in a
manner sensitive to their maturity and needs.
5. The patient is in the best position to anticipate the wishes of family
members, and members' right not to know should be considered as
part of the decision to disclose genetic risk information.
What is the role of health professionals in the disclosure
of genetic risk information within the family?
A patient seeking genetic testing or information about ge-
netic risks will likely communicate with a number of health
professionals. A personal physician first approached about
the issue might refer the patient to a genetic specialist, who
might also incorporate the services of a genetic counsellor.
What role do any or all of these professionals have in the
communication of genetic risk information to a patient's
family?
The duty to protect patient privacy and maintain confi-
dentiality has been a cornerstone of the physician–patient
relationship since the advent of the Hippocratic Oath (Met-
calfe et al. 2008). Based on the underlying values of indi-
vidual autonomy, trust, and respect for confidentiality,
today's guidelines governing the relationship between
patients and health care professionals dictate that informa-
tion obtained during the course of the relationship will not
be disclosed to third parties unless expressly authorized by
the patient or as required by law. Although much has been
made of the potential ability or duty (ethical or legal) of
health professionals to disclose genetic information without
the permission of the patient (Lucassen and Parker 2010),
for the purposes of this document, we are referring to health
professional disclosure or participation in the disclosure
process with the consent of the patient. The policy positions
and literature analyzed below often address both contexts
together.
Such a function of physicians and other health professio-
nals has the support of professional associations (Canadian
Nurses Association 2008; Canadian Medical Association
2004; Canadian Association of Genetic Counsellors 2006).
The American Medical Association (AMA) proposes that
patients and physicians discuss, prior to testing, the neces-
sity of disclosing test outcomes to family members (Amer-
ican Medical Association Council on Ethical and Judicial
Affairs 2008; Taub et al. 2004). The AMA further empha-
sizes that the role of the physician is to educate the patient
about the risks of not communicating and facilitating com-
munication with family members where necessary.
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The Nuffield Council on Bioethics in the UK also advo-
cates a role for health professionals apart from informing
family members without the consent of a patient:
“We recommend that… health professionals should
seek to persuade individuals, if persuasion should be
necessary, to allow the disclosure of relevant genetic
information to other family members. They should
also seek to ensure that treatment, counseling and
other appropriate support are made available to those
to whom such unsought information is disclosed.”
(Nuffield Council on Bioethics 1993)
In 2006, the council further raised the possibility of a
system that “assumes that relevant information will be dis-
closed to all affected parties unless there is good reason
(such as risk of harm) for it to be withheld” (Nuffield
Council on Bioethics 2006).
The Joint Committee on Medical Genetics further
strengthens the British position on intrafamilial communi-
cation by advocating for a discussion of intrafamilial dis-
closure during the consent process to ensure patients have
an understanding of the potential implications of genetic
information for their families (Royal College of Physicians
et al. 2011). It also notes that “[t]he assumption that confi-
dentiality is always paramount is as inappropriate as the
assumption that disclosure is always permissible, and the
decision will need to be tailored to the individual circum-
stances of the case,” thereby raising the potential for familial
disclosure without the consent of the patient (Royal College
of Physicians et al. 2011). Likewise, the General Medical
Council foresees instances when patients will not disclose
and states that physicians may balance the duty to care for
the patient with the duty to protect third parties from harm,
implying that if the harm is serious enough, confidentiality
may be breached (General Medical Council 2009).
Australia permits disclosure to family without the con-
sent of the patient in certain circumstances and provides
detailed guidelines to this effect (Government of Australia
2009). Although these guidelines permit such disclosure,
medical practitioners should encourage patients to disclose
to families themselves or to consent to the practitioner's
disclosure. Failing this, practitioners can proceed with dis-
closure without consent in limited circumstances.
Others have advocated for a different approach in an
effort to promote communication of genetic information
within families (Doukas and Berg 2001). For example, the
family covenant, a health care agreement among patients
within a family and their family physician, is one model
proposed to lessen the absolute confidentiality of genetic
information between physician and patient (Doukas and
Berg 2001). In this model, the family as a whole is the unit
of care and members negotiate the obligations of physician
and family members among each other at the outset. Thus, if
a patient in the covenant obtains medical information, such
as genetic test results, that has relevance for the physical
health of other family members, the covenant may foresee
an obligation by the patient to share this information. The
consequences if the patient repudiates the covenant and
refuses to disclose are problematic: the physician would still
likely be ethically and legally required to maintain confi-
dentiality unless, in the circumstances of genetic testing, the
jurisdiction permitted disclosure to third parties who may be
at risk of harm. However, these covenants would at least
permit families and physicians to have discussions pretest-
ing about its implications and the potential for family mem-
bers to be tested for a genetic predisposition.
In sum, health professionals still have a significant role to
play in facilitating intrafamilial communication of potential
genetic risk for hereditary breast and ovarian cancer, wheth-
er or not they otherwise have the legal or ethical obligation
to directly inform patients' families of this information. For
one, they can inform patients before and after testing about
the potential impact the results could have on family
(Cheung et al. 2010) and the potential that family members
might not want to know (an exercise of the right not to
know). They can also offer to aid patients with their com-
munication (Nycum et al. 2009b; Lacroix et al. 2008), such
as being present when the patient discloses to answer any
questions the family member(s) might have. This could be
especially helpful to assist patients and their families under-
stand what the results really mean to the family, rather than
relying on preconceptions held by the family which might
be inaccurate (Lacroix et al. 2008). By providing informa-
tion and guidance, health professionals might also be per-
suasive in encouraging patients to inform extended family
members, rather than just their immediate families, as
patients do not always have the urge to do so (Werner-Lin
2007).
While frontline delivery health care professionals have an
essential role to play in leading such discussions, at present,
they may be ill equipped to take on such a role (McGivern et
al. 2004). For example, nearly half of all nurses and one
third of physicians practicing in Canada reported in 2005
having no formal training in genetics (Bottorff et al. 2005).
The ability of health care professionals to communicate risk
and patients' ability to understand risk are factors that have
been shown to influence intrafamilial communication of
breast cancer risk among families (Plon et al. 2011). It can
be challenging for health care professionals to communicate
risk information, and misunderstandings about genetic risk
for breast cancer have been reported (Cheung et al. 2010)
and can be amplified when sharing the information with
relatives (Ahmed et al. 2012). Factors such as age, gender,
culture, and education have been shown to influence per-
ception and ability to comprehend risk (Vos et al. 2011).
Given the rapidly evolving nature of genetic risk
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information and the complexity of the subject, it is clear that
many health care professionals will require additional train-
ing and support in order to facilitate discussions with their
patients about genetic risk and genetic testing (Sussner et al.
2011).
Points to consider: role of health professionals
1. Health professionals have a considerable role to play in promoting
intrafamilial communication and can:
(a) Prior to testing, inform patients of the risk indicated by genetic
information, both for themselves and for family members
(b) Offer to aid patients in communicating genetic risk information to
the family or refer them to someone who can, if a patient so requests
(c) Attempt to persuade patients who are uncomfortable with
disclosing genetic risk information that such disclosures might be
necessary, even to relatives with whom the patient does not have a
close relationship
2. Guidelines and training programs should be developed to assist
health professionals in discussing the communication needs of
patients.
3. Health professionals may decide, depending on relevant legal and
ethical considerations, to override a patient's objection to informing
family members and inform them him or herself. However, both the
professional and patient are best served by the patient informing his
or her own family members, or at very least authorizing a health
professional to do so.
Conclusion
Knowledge of one's risk and genetic information is an
important step towards early detection or prevention of
hereditary breast cancer. Information about risk can come
from family history, from a family member who has been
tested for a genetic mutation, or from use of a risk prediction
model. Although the only way to know for sure that one has
the same mutation is to be tested or diagnosed, often it is
these other various sources of information that lead a person
to be tested in the first place. It has thus been questioned
whether a person who knows or strongly suspects they carry
a mutation must share this information with others in their
family.
In brief, we have discussed a number of key consider-
ations that must be addressed when dealing with intrafami-
lial communication. Based on a review of the relevant
literature and of laws and guidelines from the USA, Canada,
the UK, Australia, and various medical organizations, we
have highlighted important points to consider when deter-
mining how to address intrafamilial communication of ge-
netic risk in the clinical setting. To summarize, any duty on
patients to disclose genetic risk information to family mem-
bers should be personal, not legal, and should apply to a
broad spectrum of family members and information. Health
professionals can have an important role in conveying
information to the patient, but the final decision of what,
how, to whom, and when to disclose should remain with the
patient to the extent possible. Genetic risk information is
sensitive medical information and implicates both patients
and others in their family. Strong reasons have not yet been
provided to completely deprive patients of their traditional
control over what happens to this information.
This represents only an initial step towards fostering
better communication within families. Indeed, the lack of
consensus about what constitutes genetic information or the
“genetic” family, or even discussion of the issue of intra-
familial communication, in various jurisdictions and organ-
izations that otherwise have laws, regulations, or guidelines
for genetic testing and disclosure of results speaks to both
the novelty and complexity of this issue. We do not claim to
have comprehensively analyzed intrafamilial communica-
tion. Rather, we suggest that additional research is needed
to determine the best methods for encouraging this commu-
nication and motivations for disclosing or not and provide
points to consider when developing a solution, considering
the complexity of human relationships and the probabilistic
nature of genetic information. With the promise of continu-
ing advances in genetic discoveries and medical treatment,
the matter of intrafamilial disclosure of risk for hereditary
breast cancer is here to stay.
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